LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR‐128/CD151 pathway in hepatocellular carcinoma

2018/08/21 by Pengfei Zhang, Peng‐Fei Zhang, Fei Wang +9 · 189 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Biology #Biomarker #Cancer #Cancer research #Cancer-related molecular mechanisms research #Carcinogenesis #Downregulation and upregulation #Epithelial–mesenchymal transition #Gene #Gene knockdown #Hepatocellular carcinoma #Internal medicine #Long non-coding RNA #Medicine #Metastasis #MicroRNA in disease regulation #RNA modifications and cancer #Small nucleolar RNA #Sorafenib

paper · doi:10.1002/jcp.27095

published in Journal of Cellular Physiology 234(3), 2788-2794 (Wiley)

openalex publication_date 2018/08/21 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

Dysregulation of long noncoding RNAs (lncRNAs) plays important roles in carcinogenesis and tumor progression, including hepatocellular carcinoma (HCC). Small nucleolar RNA host gene 3 (SNHG3) has been considered as an lncRNA to be associated with a poor prognosis in patients with HCC. Here, we reported that SNHG3 expression was significantly higher in the highly metastatic HCC (HCCLM3) cells compared with the lowly metastatic HCC cells (Hep3B and PLC/PRF/5). Furthermore, forced expression of SNHG3 promoted cell invasion, epithelial-mesenchymal transition (EMT), and sorafenib resistance in HCC. Moreover, SNHG3 overexpression induced HCC cells EMT via miR-128/CD151 cascade activation. Clinically, our data revealed that increased SNHG3 expression is correlated with poor HCC survival outcomes and sorafenib response. These data suggest that SNHG3 may be a novel therapeutic target and a biomarker for predicting response to sorafenib treatment of HCC.

Citations

• Cancer statistics, 2016

Cited by

• Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p. [europepmc]
• Long non-coding RNA SNHG3 promotes progression of gastric cancer by regulating neighboring MED18 gene methylation. [europepmc]
• Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition. [europepmc]
• SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma. [europepmc]
• MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. [europepmc]
• The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. [europepmc]
• Long non-coding small nucleolar RNA host genes in digestive cancers. [europepmc]
• The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. [europepmc]
• Long non-coding RNA PSMA3-AS1 promotes malignant phenotypes of esophageal cancer by modulating the miR-101/EZH2 axis as a ceRNA. [europepmc]
• Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression. [europepmc]
• lncRNA SNHG3 acts as a novel Tumor Suppressor and regulates Tumor Proliferation and Metastasis via AKT/mTOR/ERK pathway in Papillary Thyroid Carcinoma. [europepmc]
• LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway. [europepmc]
• Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma. [europepmc]
• LncRNA SNHG3, a potential oncogene in human cancers. [europepmc]
• Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. [europepmc]
• TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. [europepmc]
• MicroRNAs and Circular RNAs in Lipoprotein Metabolism. [europepmc]
• Cancer drug resistance induced by EMT: novel therapeutic strategies. [europepmc]
• The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer. [europepmc]
• Loss of SNORA73 reprograms cellular metabolism and protects against steatohepatitis. [europepmc]
• LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis. [europepmc]
• Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs. [europepmc]
• Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights. [europepmc]
• Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma. [europepmc]
• Signaling pathways in liver cancer: pathogenesis and targeted therapy. [europepmc]

Related

• LncRNA SNHG5/miR‐363‐3p/USP28 Axis Promotes Lung Adenocarcinoma Progression Through Enhancing β‐Catenin Stabilization
• LincRNA-miR interactions in hepatocellular carcinoma: comprehensive review and in silico analysis: a step toward ncRNA precision
• Noncoding RNAs and programmed cell death in hepatocellular carcinoma: Significant role of epigenetic modifications in prognosis, chemoresistance, and tumor recurrence rate
• NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL‐6/JAK2/STAT3 pathway activation
• LncRNA HAGLR regulates gastric cancer progression by regulating the miR-20a-5p/E2F1 axis